Lucid Diagnostics (NASDAQ:LUCD) Earns "Buy" Rating from BTIG Research

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at BTIG Research in a report released on Friday, Benzinga reports.

LUCD has been the subject of several other reports. Weiss Ratings cut shares of Lucid Diagnostics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 18th. Needham & Company LLC restated a "buy" rating on shares of Lucid Diagnostics in a research report on Thursday, October 1st. Finally, Wall Street Zen downgraded shares of Lucid Diagnostics from a "hold" rating to a "sell" rating in a report on Saturday, July 4th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Lucid Diagnostics presently has an average rating of "Moderate Buy" and a consensus price target of $4.19.

Lucid Diagnostics Stock Down 12.5%

LUCD stock traded down $0.06 during trading hours on Friday, hitting $0.44. The company's stock had a trading volume of 10,192,234 shares, compared to its average volume of 2,361,490. The stock has a 50 day moving average price of $0.75 and a two-hundred day moving average price of $1.04. Lucid Diagnostics has a 12 month low of $0.30 and a 12 month high of $1.63. The company has a market capitalization of $89.04 million, a PE ratio of -0.93 and a beta of 1.12.

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.06). The business had revenue of $1.47 million during the quarter, compared to the consensus estimate of $1.43 million. Sell-side analysts expect that Lucid Diagnostics will post -0.23 earnings per share for the current year.

Institutional Investors Weigh In On Lucid Diagnostics

Several institutional investors and hedge funds have recently bought and sold shares of LUCD. Sequoia Financial Advisors LLC acquired a new position in shares of Lucid Diagnostics in the 2nd quarter valued at $99,000. XML Financial LLC boosted its position in shares of Lucid Diagnostics by 44.8% during the 2nd quarter. XML Financial LLC now owns 323,195 shares of the company's stock valued at $346,000 after acquiring an additional 100,000 shares in the last quarter. Two Sigma Securities LLC bought a new stake in Lucid Diagnostics in the second quarter valued at about $43,000. Alyeska Investment Group L.P. bought a new stake in Lucid Diagnostics in the second quarter valued at about $9,477,000. Finally, Jefferies Financial Group Inc. acquired a new position in Lucid Diagnostics in the second quarter worth about $139,000. Institutional investors own 74.01% of the company's stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc NASDAQ: LUCD is a medical diagnostics company focused on improving the detection of esophageal disease. The company develops and commercializes diagnostic technologies intended to identify patients at elevated risk of esophageal cancer, particularly those with gastroesophageal reflux disease (GERD).

Lucid's principal products include EsoGuard, a laboratory-developed DNA test that analyzes cells collected from the esophagus for molecular changes associated with Barrett's esophagus and esophageal cancer risk, and EsoCheck, a swallowable, balloon-based device designed to collect cells from the esophageal lining.